RxDoctor Payments Data

Saras Rustagi

Corneal and Contact Management · West New York, NJNPI 1427110311

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Coopervision Inc. at 29.4% of the total.

$3,109in general payments, 2019–2025

Across 49 payments — averaging $63.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$915
  • Sight Sciences, Inc.$506
  • Glaukos Corporation$454
  • AbbVie$363
  • Lumenis BE Inc$310
  • Alcon$200
  • plus $361 from 6 others

What the payments were for

  • Food & beverage$3,08099%
  • Entertainment$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,109 in reported general payments places this provider in the 75th percentile of 45 corneal and contact management providers in New Jersey.

See all corneal and contact management providers in New Jersey

Medicare billing

Part B allowed, 2024
$111,202
Medicare patients
155
Services billed
1,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Timolol Maleate16$1,179

Paid to pharmacies, not to this prescriber.

Other corneal and contact management in West New York

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →